Neurol. praxi. 2016;17(4):250-253 | DOI: 10.36290/neu.2016.052

Glatiramer acetate and three case reports

MUDr. Zbyšek Pavelek1, MUDr. Pavel Ryška, Ph.D.2, doc. MUDr. Martin Vališ, Ph.D.1
1 Neurologická klinika LF a FN Hradec Králové
2 Radiologická klinika LF a FN Hradec Králové

Multiple sclerosis is a chronic inflammatory demyelinating disease which affect central nervous system. This autoimmune disease

manifests itself with various symptoms. Glatiramer acetate (Copaxone) is a drug of the the first line treatment for relaps/remitent

type of multiple sclerosis or clinically isolated syndrome. This review explore the mechanism of action of glatiramer acetate in

treatment of multiple sclerosis, its indication for treatment, use and possible side effects too. We report three cases from our own

patients base through we demonstrate possible use of glatiramer acetate.

Keywords: multiple sclerosis, glatiramer acetate

Published: August 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pavelek Z, Ryška P, Vališ M. Glatiramer acetate and three case reports. Neurol. praxi. 2016;17(4):250-253. doi: 10.36290/neu.2016.052.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Buraga I, Popovici R. Multiple sclerosis and pregnancy: current considerations. Scientific World J 2014; 2014: 513160. Go to original source... Go to PubMed...
    2. Krejsek J. Novinky v patogenezi roztroušené sklerózy. Co je skryto za disabilitou pacientů s RS. Remedia, 2014: S2-4.
    3. Pavelek Z, Krejsek J, Vališ M. Role T a B lymfocytů v patogenezi roztroušené sklerózy. Neurol. praxi 2016; 17(2):100-103. Go to original source...
    4. Steinman L. Multiple sclerosis: a two-stage disease. Nature Immunol. 2001; 2(9): 762-764. Go to original source... Go to PubMed...
    5. Wolinsky JS, Borresen TE, Dietrich DW, Wynn D, Sidi Y, Steinerman JR, Knappertz V, Kolodny S; GLACIER Study Group. GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord 2015; 4: 370-376. Go to original source... Go to PubMed...
    6. Ziemssen T, Schrempf W. Glatiramer acetate: mechanisms of action in multiple sclerosis. Int Rev Neurobiol. 2007; 79: 537-570. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.